Filtered By:
Drug: Aspirin
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 230 results found since Jan 2013.
Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome
Exp Ther Med. 2022 Jun;23(6):378. doi: 10.3892/etm.2022.11305. Epub 2022 Apr 8.ABSTRACTThe link between inflammation and acute coronary syndrome (ACS) remains to be sufficiently elucidated. It has been previously suggested that there is an inflammatory process associated with ACS. Pentoxifylline, a methylxanthine derivate, is known to delay the progression of atherosclerosis and reduce the risk of vascular events, especially by modulating the systemic inflammatory response. The present study is a single-blind, randomized, prospective study of pentoxifylline 400 mg three times a day (TID) added to standard therapy vs. stand...
Source: Experimental and Therapeutic Medicine - May 2, 2022 Category: General Medicine Authors: Daniel Miron Brie Cristian Mornos Diduta Alina Brie Constantin Tudor Luca Lucian Petrescu Madalina Boruga Source Type: research
Data from New VOYAGER PAD Analyses at ACC.22 Reinforce Benefit of XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Peripheral Artery Disease (PAD) and Various Co-Morbid Conditions
RARITAN, N.J., April 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from new analyses from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefit of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) in reducing severe vascular events in patients with PAD after lower-extremity revascularization (LER), a procedure that restores blood flow to the legs. Data from the two analyses demonstrate the role that the XARELTO® vascular dose plays in PAD patients with and without chronic kidney disease (CKD) and in PAD patients with and ...
Source: Johnson and Johnson - April 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - March 23, 2022 Category: Cardiology Source Type: research
Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory: Report of the AAN Guideline Subcommittee
Neurology. 2022 Mar 22;98(12):486-498. doi: 10.1212/WNL.0000000000200030.ABSTRACTBACKGROUND AND OBJECTIVES: To review treatments for reducing the risk of recurrent stroke or death in patients with symptomatic intracranial atherosclerotic arterial stenosis (sICAS).METHODS: The development of this practice advisory followed the process outlined in the American Academy of Neurology Clinical Practice Guideline Process Manual, 2011 Edition, as amended. The systematic review included studies through November 2020. Recommendations were based on evidence, related evidence, principles of care, and inferences.MAJOR RECOMMENDATIONS: ...
Source: Atherosclerosis - March 22, 2022 Category: Cardiology Authors: Tanya N Turan Osama O Zaidat Gary S Gronseth Marc I Chimowitz Antonio Culebras Anthony J Furlan Larry B Goldstein Nestor R Gonzalez Julius G Latorre Steven R Mess é Thanh N Nguyen Rajbeer S Sangha Michael J Schneck Aneesh B Singhal Lawrence R Wechsler Al Source Type: research
An Updated Review of Cardiovascular Events in Giant Cell Arteritis
J Clin Med. 2022 Feb 15;11(4):1005. doi: 10.3390/jcm11041005.ABSTRACTGiant cell arteritis (GCA) is a systemic vasculitis with a direct and indirect increased risk of acute and chronic vascular events, affecting large and medium vessels, and responsible for most of the morbidity and mortality of this disease. We aimed in this review to provide an updated synthesis of knowledge regarding cardiovascular events observed in GCA. By definition, GCA patients are over 50 and often over 70 years old, and subsequently also present age-related cardiovascular risk factors. In addition, the systemic and vascular inflammation as well as...
Source: Atherosclerosis - February 25, 2022 Category: Cardiology Authors: Hubert de Boysson Achille Aouba Source Type: research
Determinants of Incident Atherosclerotic Cardiovascular Disease Events Among Those With Absent Coronary Artery Calcium: Multi-Ethnic Study of Atherosclerosis
Conclusions: Current cigarette smoking, diabetes mellitus, and hypertension are independently associated with incident ASCVD over 16-year follow-up among those with CAC=0. Family history of premature ASCVD may be associated with ASCVD risk among women only.PMID:34879218 | DOI:10.1161/CIRCULATIONAHA.121.056705
Source: Atherosclerosis - December 8, 2021 Category: Cardiology Authors: Mahmoud Al Rifai Michael J Blaha Vijay Nambi Steven J C Shea Erin D Michos Roger S Blumenthal Christie M Ballantyne Moyses Szklo Philip Greenland Michael D Miedema Khurram Nasir Jerome I Rotter Xiuqing Guo Jie Yao Wendy S Post Salim S Virani Source Type: research
Statin and dual antiplatelet therapy for the prevention of early neurological deterioration and recurrent stroke in branch atheromatous disease: a protocol for a prospective single-arm study using a historical control for comparison
Introduction
Branch atheromatous disease (BAD) contributes to small-vessel occlusion in cases of occlusion or stenosis of large calibre penetrating arteries, and it is associated with a higher possibility of early neurological deterioration (END) and recurrent stroke in acute ischaemic stroke. As the pathology of BAD is due to atherosclerosis, we postulate that early intensive medical treatment with dual antiplatelet therapy (DAPT) and high-intensity statins may prevent END and recurrent stroke in acute small subcortical infarction caused by BAD.
Methods and analysis
In this prospective, single-centre, open-label, non-ran...
Source: BMJ Open - November 26, 2021 Category: General Medicine Authors: Huang, Y.-C., Lee, J.-D., Weng, H.-H., Lin, L.-C., Tsai, Y.-H., Yang, J.-T. Tags: Open access, Neurology Source Type: research
COVID-19 Infection and Recurrent Stroke in Young Patients With Protein S Deficiency: A Case Report
Conclusions:
SARS-CoV-2 infection potentializes the prothrombotic effect and vascular inflammation by accentuating protein S deficit. The place of steroids seems justifiable in the presence of symptoms of vasculitis in brain imaging.
Source: The Neurologist - November 1, 2021 Category: Neurology Tags: Case Report/Case Series Source Type: research
U.S. Task Force Reconsiders Daily Low-Dose Aspirin Use for Preventing Heart Attacks in Adults Over 60
Older adults without heart disease shouldn’t take daily low-dose aspirin to prevent a first heart attack or stroke, an influential health guidelines group said in preliminary updated advice released Tuesday.
Bleeding risks for adults in their 60s and up who haven’t had a heart attack or stroke outweigh any potential benefits from aspirin, the U.S. Preventive Services Task Force said in its draft guidance.
For the first time, the panel said there may be a small benefit for adults in their 40s who have no bleeding risks. For those in their 50s, the panel softened advice and said evidence of benefit is less clear....
Source: TIME: Health - October 12, 2021 Category: Consumer Health News Authors: Lindsey Taylor/AP Tags: Uncategorized healthscienceclimate Research wire Source Type: news
Comparing pharmacotherapy in MINOCA versus medically managed obstructive acute coronary syndrome
This study uniquely compares the management and outcomes of MINOCA patients with a medically managed obstructive ACS (M-ACS) population. We retrospectively analysed registry data for consecutive patients admitted to the Gold Coast University Hospital with ACS requiring coronary angiography and identified patients with MINOCA and M-ACS. Baseline characteristics, pharmacological therapy and in-hospital outcomes were compared. In hospital outcomes were composite NACE, heart failure, stroke and major bleeding. Multivariate regression analysis was also performed to identify independent predictors of MINOCA. Multivariate regress...
Source: Heart and Vessels - October 10, 2021 Category: Cardiology Source Type: research
